Fig 2: Survival curves and forest plots. (A) Kaplan-Meier curves for MACEs and (B) rehospitalization for HF in the low Drp1 group (Drp1 ≤2.66 ng/ml, red line) vs. the high Drp1 group (Drp1 >2.66 ng/ml; blue line) at 6-month follow-up. Forest plots revealing the association between Drp1 at the threshold of >2.66 ng/ml and (C) a composited MACE and (D) rehospitalization for HF. MACEs, major adverse cardiac events; HF, heart failure; OR, odds ratio; LDL, lipoprotein; RA, right atrium; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; IHD, ischemic heart disease.

Fig 3: Column graphs and the receiver operating characteristic (ROC) curves. (A) Quantifications of serum Drp1 concentrations in patients of heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), respectively. *p < 0.05, Student’s t-test. (B) Quantifications of serum Drp1 concentrations in different etiologies of HF. IHD, ischemic heart disease; NS, no significance, one-way analysis of variance. (C) ROC curve for serum Drp1 in distinguishing HFpEF and HFrEF. (D) ROC curve for serum Drp1 to assess its indictive effects for freedom from the risk of composite endpoint at 6-month follow-up. The cutoff value of serum Drp1 is 2.5 ng/mL. AUC, area under the curve; Drp1, dynamin-related protein 1.

Fig 4: ROC curve of Drp1 level for predicting the freedom from the risk of MACEs after 6-month follow-up. The AUC was 0.752 and the optimal cut-off value was 2.66 ng/ml (sensitivity 65.9%; specificity 87%). ROC, receiver operating characteristic; Drp1, dynamin-related protein 1; MACEs, major adverse cardiac events; AUC, area under the curve.

Fig 5: A flow chart of the selection of patients enrolled in the present study. HF, heart failure; ROC, receiver operating characteristic; Drp1, dynamin-related protein 1; MACEs, major adverse cardiac events.